TGF-β negatively affects the maintenance and expansion of hematopoietic stem cells ex vivo and its inhibition has been widely studied as a treatment for numerous hematopoietic disorders and cancers. Current inhibitory strategies (small molecule ATP competitors and neutralizing antibodies) are compared to a novel cell-permeable peptide-based inhibitor of TGF-β RI. Multiple levels of assay from biochemical to functional are utilized with the aim of applying the most successful inhibitor to hematopoietic stem cell culture. The neutralizing antibody proved ineffective in the short-term biochemical assay but was extremely effective at neutralizing TGF-β signalling in proliferation and hematopoietic colony-forming cell assays with no evidence of toxicity. The small molecule inhibitors (SD-208 and Pyrazole TGF-β RI inhibitor) were equally effective at micromolar levels in all forms of assay, with SD-208 being slightly more potent. The novel peptide inhibitor proved ineffective in all assays, which is likely a result of its rapid degradation in live cells.

Cellular stress invokes a protective response in which heat shock factor 1 (HSF1) is activated to increase heat shock protein (Hsp) expression. HSF1 exists as a latent monomer in unstressed cells. Upon stress HSF1 forms homotrimers, increasing its affinity for the heat shock DNA element upstream of all Hsp genes. A second conformational change is required for HSF1 to gain transcriptional competence. During prolonged heat shock or following the resumption of normal conditions HSF1 DNA-binding and transcriptional activities are reduced and HSF1 returns to the monomeric state in a process called attenuation. During the activation/deactivation cycle HSF1 is modified by small ubiquitin-related modifier (SUMO-1) conjugation and undergoes several phosphorylation and dephosphorylation events that modulate HSF1 activity. Hyperphosphorylation of HSF1 is hypothesized to trigger HSF1 transcriptional activity. HSF1 also interacts with a dynamic series of Hsp90/Hsp70-based chaperone heterocomplexes that negatively regulate DNA-binding, and transcriptional activity, and promote attenuation. This thesis was aimed at characterizing the mechanisms regulating HSF1 DNA-binding, and transcriptional activity. Expression of human HSF1 in Xenopus oocytes altered the set-point of DNA-binding in response to heat indicating that both the cellular environment and innate properties of the molecule allow HSF1 to set its activation/deactivation set-point in response to stress in vivo. HSF1 DNA-binding but not transcription was activated in oocytes treated with a high temperature heat shock. Further characterization of this observation determined that HSF1 activated by a brief high temperature heat shock inhibited transcriptionally competent HSF1 from activating transcription. It was hypothesized that this phenomenon exists to ensure the eventual death of the cell due to the accumulation of excessive damage and potential mutation caused by severe stress. The most significant observation made in this thesis is that Hsp expression was detected in oocytes injected with reporter plasmid only during recovery from a high temperature heat shock. These results led to the proposal of a model in which HSF1 trimers are either assembled in a transcriptionally incompetent form or one that has the potential to become transcriptionally competent during stress, prior to DNA-binding. The identity of HSF1-binding proteins that interact with HSF1 at different stages of activation/deactivation was characterized in an effort to assign regulatory roles to these proteins. HSF1 was detected in a high molecular weight complex (350-600 kDa) during all phases of the activation/deactivation cycle. HSF1 at different stages of activation was tested for interaction with specific molecular chaperones by electrophoretic mobility supershift analysis. Hsp90, p23, FKBP52, Hip and Hop are all associated with transcriptionally active and inactive HSF1 suggesting that interaction of HSF1 with any of these molecules does not activate HSF1 transcriptional activity. These results do not exclude the possibility that the function of these molecular chaperones may change during activation of HSF1 transcription or that post-translational modifications may be the primary mechanism that drives HSF1 from a transcriptionally inactive to active form.

Cellular stress invokes a protective response in which heat shock factor 1 (HSF1) is activated to increase heat shock protein (Hsp) expression. HSF1 exists as a latent monomer in unstressed cells. Upon stress HSF1 forms homotrimers, increasing its affinity for the heat shock DNA element upstream of all Hsp genes. A second conformational change is required for HSF1 to gain transcriptional competence. During prolonged heat shock or following the resumption of normal conditions HSF1 DNA-binding and transcriptional activities are reduced and HSF1 returns to the monomeric state in a process called attenuation. During the activation/deactivation cycle HSF1 is modified by small ubiquitin-related modifier (SUMO-1) conjugation and undergoes several phosphorylation and dephosphorylation events that modulate HSF1 activity. Hyperphosphorylation of HSF1 is hypothesized to trigger HSF1 transcriptional activity. HSF1 also interacts with a dynamic series of Hsp90/Hsp70-based chaperone heterocomplexes that negatively regulate DNA-binding, and transcriptional activity, and promote attenuation. This thesis was aimed at characterizing the mechanisms regulating HSF1 DNA-binding, and transcriptional activity. Expression of human HSF1 in Xenopus oocytes altered the set-point of DNA-binding in response to heat indicating that both the cellular environment and innate properties of the molecule allow HSF1 to set its activation/deactivation set-point in response to stress in vivo. HSF1 DNA-binding but not transcription was activated in oocytes treated with a high temperature heat shock. Further characterization of this observation determined that HSF1 activated by a brief high temperature heat shock inhibited transcriptionally competent HSF1 from activating transcription. It was hypothesized that this phenomenon exists to ensure the eventual death of the cell due to the accumulation of excessive damage and potential mutation caused by severe stress. The most significant observation made in this thesis is that Hsp expression was detected in oocytes injected with reporter plasmid only during recovery from a high temperature heat shock. These results led to the proposal of a model in which HSF1 trimers are either assembled in a transcriptionally incompetent form or one that has the potential to become transcriptionally competent during stress, prior to DNA-binding. The identity of HSF1-binding proteins that interact with HSF1 at different stages of activation/deactivation was characterized in an effort to assign regulatory roles to these proteins. HSF1 was detected in a high molecular weight complex (350-600 kDa) during all phases of the activation/deactivation cycle. HSF1 at different stages of activation was tested for interaction with specific molecular chaperones by electrophoretic mobility supershift analysis. Hsp90, p23, FKBP52, Hip and Hop are all associated with transcriptionally active and inactive HSF1 suggesting that interaction of HSF1 with any of these molecules does not activate HSF1 transcriptional activity. These results do not exclude the possibility that the function of these molecular chaperones may change during activation of HSF1 transcription or that post-translational modifications may be the primary mechanism that drives HSF1 from a transcriptionally inactive to active form.

TGF-β negatively affects the maintenance and expansion of hematopoietic stem cells ex vivo and its inhibition has been widely studied as a treatment for numerous hematopoietic disorders and cancers. Current inhibitory strategies (small molecule ATP competitors and neutralizing antibodies) are compared to a novel cell-permeable peptide-based inhibitor of TGF-β RI. Multiple levels of assay from biochemical to functional are utilized with the aim of applying the most successful inhibitor to hematopoietic stem cell culture. The neutralizing antibody proved ineffective in the short-term biochemical assay but was extremely effective at neutralizing TGF-β signalling in proliferation and hematopoietic colony-forming cell assays with no evidence of toxicity. The small molecule inhibitors (SD-208 and Pyrazole TGF-β RI inhibitor) were equally effective at micromolar levels in all forms of assay, with SD-208 being slightly more potent. The novel peptide inhibitor proved ineffective in all assays, which is likely a result of its rapid degradation in live cells.

Understanding the specific mechanisms regulating chemotherapeutic drug anti-cancer activities will uncover novel strategies to enhance the efficacy of these drugs in clinical settings. Activating Transcription Factor 3 (ATF3) is a stress inducible gene whose expression has been associated with survival outcomes in cancer models. This study characterizes the chemotherapeutic drugs, cisplatin and Histone Deacetylase Inhibitor (HDACi), M344 as novel inducers of ATF3 expression. Cisplatin is a DNA damaging agent widely used in various tumour types including lung, head and neck, and ovarian carcinomas. The HDAC inhibitor, SAHA, has recently been approved as a single agent in the treatment of subcutaneous T-cell lymphoma and HDACis themselves show potential for synergistic anti-cancer effects when used in combination with established chemotherapeutic drugs, including cisplatin. This study evaluates the mechanisms by which cisplatin and HDACi induce ATF3, as well as the role ATF3 plays as a mediator of cisplatin-induced cytotoxicity and the enhanced cytotoxicity between HDACi and cisplatin in combination. In this study, we demonstrate that cytotoxic doses of cisplatin and carboplatin consistently induced ATF3 expression in a panel of human tumour derived cell lines. Characterization of this induction revealed a p53, BRCA1, and integrated stress response (ISR) independent mechanism, all previously implicated in stress mediated ATF3 induction. Analysis of MAPKinase pathway involvement in ATF3 induction by cisplatin revealed a MAPKinase dependent mechanism. Cisplatin treatment, in combination with specific inhibitors to each MAPKinase pathway (JNK, ERK and p38) resulted in decreased ATF3 induction at the protein level. MAPKinase pathway inhibition led to decreased ATF3 mRNA expression and a reduction in the cytotoxic effects of cisplatin as measured by MTT cell viability assay. In A549 lung carcinoma cells, targeting ATF3 with specific shRNAs also attenuated the cytotoxic effects of cisplatin. Similarly, ATF3 -/- MEFs were shown to be less sensitive to cisplatin induced cytotoxicity as compared with ATF3+/+ MEFs. Taken together, we identified cisplatin as a MAPKinase pathway dependent inducer of ATF3 whose expression regulates in part cisplatin’s cytotoxic effects. Furthermore, we demonstrated that the HDAC inhibitor M344 was also an inducer of ATF3 expression at the protein and mRNA level in the same human derived cancer cell lines. Combination treatment with M344 and cisplatin lead to increased induction of ATF3 compared with cisplatin alone. Utilizing the MTT cell viability assay, M344 treatment was also shown to enhance the cytotoxic effects of cisplatin in these cancer cell lines. Unlike cisplatin, the mechanism of ATF3 induction by M344 was found to be independent of MAPKinase pathways. Utilizing ATF4 heterozygote (+/-) and knock out (-/-) mouse embryonic fibroblast (MEF) M334 induction of ATF3 was shown to depend on the presence of ATF4, a known regulator of ATF3 expression as part of the ISR pathway. HDACi treatment did not affect the level of histone acetylation associated with the ATF3 promoter as determined through Chromatin immunoprecipitation (ChIP) analysis, suggesting that ATF3 induction was not a direct effect of HDACi mediated histone acetylation. We also demonstrated that ATF3 regulates the enhanced cytotoxicity of M344 in combination with cisplatin as evidenced by attenuation of cytotoxicity in shRNAs targeting ATF3 expressing cells. This study identifies the pro-apoptotic factor, ATF3 as a novel target of M344, as well as a mediator of the co-operative effects of cisplatin and M344 induced tumour cell cytotoxicity.

The inhibitor of apoptosis (IAP) proteins traditionally regulate programmed cell death by binding to and inhibiting caspases. Recent studies have uncovered a variety of alternate cellular roles for several IAP family members. The cellular inhibitor of apoptosis 1 (cIAP1) protein, for instance, regulates different axes of the NF-κB signalling pathway. Given the extensive functions of NF-κB signalling in muscle differentiation and regeneration, I asked if cIAP1 also plays critical roles in skeletal muscle myogenesis. In a primary myoblast cell-culture system, genetic and pharmacological approaches revealed that loss of cIAP1 dramatically increases the fusion of myoblasts into myotubes. NF-κB signalling occurs along a classical and an alternative pathway, both of which are highly active in cIAP1-/- myoblasts. Suppression of the alternative pathway attenuates myotube fusion in wildtype and cIAP1-/- myoblasts. Conversely, constitutive activation of the alternative pathway increases myoblast fusion in wildtype myoblasts. cIAP1-/- mice have greater muscle weight and size than wildtypes, as well as an increased number of muscle stem cells. These results identify cIAP1 as a regulator of myogenesis through its modulation of classical and alternative NF-κB signalling pathways. Loss of the structural protein dystrophin in the mdx mouse model of Duchenne muscular dystrophy leads to chronic degeneration of skeletal muscle. The muscle pathology is strongly influenced by NF-κB signaling. Given the roles demonstrated for cIAP1 in cell culture and in vivo, I asked whether loss of cIAP1 would influence muscle pathology in the mdx mouse. To address this question, double-mutant mice were bred lacking both cIAP1 and dystrophin (cIAP1-/-;mdx). Histological analyses revealed that double-mutant mice exhibited reduced indications of damage on several measures, as compared to single-mutant (cIAP1+/+;mdx) controls. Unexpectedly, these reductions were seen in the “slow-twitch” soleus muscle but not in the “fast-twitch” extensor digitorum longus (EDL) muscle. The improvements in pathology of double-mutant solei were associated with reductions in muscle infiltration by CD68-expressing macrophages. Finally, the double-mutant mice exhibited improved endurance and resistance to damage during treadmill-running exercise. Taken together, these results suggest that loss of cIAP1, through its multiple regulatory functions, acts to improve myogenesis and increase muscle resistance to damage.

Histone deacetylase inhibitors (HDIs) are a group of chemo-preventive and chemo-therapeutic agents that have generated significant attention in clinical trials, given their ability to selectively induce cell cycle arrest, differentiation and/or apoptosis of tumor cells. Presently, these agents are proposed to function by altering gene expression levels, primarily by promoting histone hyperacetylation and gene transcription. However, in this thesis, HDIs are reported to control the expression of genes from the c-Src kinase family and p21WAF1 by means other than transcriptional activation. <p>Overexpression and activation of c-Src, a 60kDa non-receptor tyrosine kinase, has been implicated in the development, growth, progression, and metastasis of several human cancers, especially those of the colon. Butyrate and the more specific histone deacetylase inhibitor trichostatin A (TSA) were both found to effectively inhibit the expression of c-Src mRNA and protein in a number of tumor cell lines, including those of the colon, liver and breast. Expression of the SRC oncogene is alternatively regulated by the SRC1A and SRC1 promoters. HDIs were shown to repress c-Src expression by inhibiting transcription of both of these promoters, independent of any new protein synthesis. Furthermore, butyrate and TSA similarly regulated the expression of the c-Src family kinase (SFK) members Yes, Fyn, Lyn and Lck in human colon cancer cell lines. In addition, TATA binding protein (TBP) associated factor 1 (TAF1) was shown to be necessary for basal transcription of the SRC1A, YES and LYN promoters, but was not required for HDI mediated repression. <p>Induction of the potent cyclin dependent kinase inhibitor p21WAF1 has been identified to be a key feature of HDI mediated cell cycle arrest. The level of p21WAF1 expression has been extensively reported to be directly upregulated by HDIs in a p53 independent manner that requires Sp family binding sites in the p21WAF1 proximal promoter to induce transcription. However, HDIs were shown to be capable of inducing p21WAF1 gene expression, dependent on new protein synthesis, by increasing mRNA stability. To date, p21WAF1 mRNA stability has been extensively studied and a number of cis-acting elements in the 3 untranslated region (UTR) of the p21WAF1 mRNA have been implicated in the regulation of mRNA stability, such as AU rich elements (AREs) and a 42 nucleotide HuD/Elav binding element. Similarly, in this work, two novel cis-acting elements were identified in the 3 UTR of p21WAF1 and were shown to facilitate basal and HDI induced post-transcriptional regulation of p21WAF1 mRNA stability in HepG2 cells. Collectively, these studies highlight the intricacy of HDI mediated effects and challenge the preconceptions regarding the molecular mechanism of these anti-tumor agents.

<p>Functional genomic analyses provide information that allows hypotheses to be formulated on protein function. These hypotheses, however, need to be validated using reverse genetic approaches, which are difficult to perform on a large scale and in diploid organisms. To address this problem, we developed a genetic screen to rapidly isolate lariat peptides that function as trans dominant inhibitors of protein function.</p> <p>We engineered intein proteins to genetically produce lariats. A lariat consists of a lactone peptide covalently attached to a linear peptide. Cyclizing peptides with a lactone bond imposes a constraint even within the reducing environment found inside of cells. The covalently attached linear peptide provides a site for fusing protein moieties. We fused a transcriptional activation domain to a combinatorial lactone peptide, which allowed combinatorial lariat libraries to be screened for protein interactions using the yeast two-hybrid assay.</p> <p>We confirmed that the intein processed in yeast using Western blot analysis. A chemoselective ring opening of the lactone bond with heavy water, followed by mass spectrometry analysis showed that ~ 44% of purified lariat contained an intact lactone bond. To improve the stability of the lactone bond, we introduced mutations into the engineered intein and analyzed their processing and stability by mass spectrometery. Several mutations were identified that increased the amount of intact lariat.</p> <p>Combinatorial libraries of lactone peptides were generated and screened using the yeast-two-hybrid interaction trap. Lactone cyclic peptides that bound to a number of different targets including LexA, Jak2, and Riz1 were isolated. A lactone cyclic peptide isolated against the bacterial repressor protein LexA was characterized. LexA regulates bacterial SOS response and LexA mutants that cannot undergo autoproteolyis make bacteria more sensitive to, and inhibit resistance against cytotoxic reagents. The anti-LexA lariat interacted with LexA with a dissociation constant of 37 µM by surface plasmon resonance. The lactone constraint was determined to be required for the interaction of the anti-LexA L2 lariat with LexA in the yeast-two-hybrid assay. Alanine scanning showed that only two amino acids (G8 and E9) in the anti-LexA L2 sequence (1-SRSWDLPGEY-10) were not required for the interaction with LexA. The interaction of the anti-LexA lariat with LexA in vivo was confirmed by chromatin precipitation of the lactone peptide-LexA-DNA complex. The anti-microbial properties of the anti-LexA lariat were also characterized. The anti-LexA lariat potentiated the activity of a DNA damaging agent mitomycin C and inhibited the cleavage of LexA, preventing the SOS response pathway from being activated.</p> <p>In summary, lariats possess desired traits for characterizing the function and therapeutic potential of proteins. The ability to genetically and chemically synthesize lariats allows the lariat transcription activation domain to be replaced by other peptide and chemical moieties such as affinity tags, fluorescent molecules, localization sequences, et cetera, which give them advantages over head to tail cyclized peptides, which have no free end to attach moieties.</p>

none

C1-esterase inhibitor (C1-inh) can inhibitor the first complement protein as C1s and C1r activity to reach adjust classical pathway, avoid excessive activation of the complement system to cause disease. C1-inhibitor protein composed of 478 amino acids with two domains: C terminal domain (serpin domain) and N terminal domain. The early focus has been to angioedema associated with cancer found so far. So the purpose of the study was to investigate whether the C1-inh cause for the breast cancer cell proliferation and migration. We use recombinant gene transform Escherichia coli strain BL21(DE3) and expression. Recombinant protein was purified using affinity column. Influence of proliferation and migration on breast cancer cells were tested by purified recombinant C1-inh. In breast cancer cell proliferation results showed, C1-inh significant proliferation of breast cancer, and when the higher concentration, the longer the incubation time, the remarkable effect of promoting proliferation is even more obvious. The results in breast cancer cell migration is also significant in the C1-inh to promote breast cancer cell migration, and when the higher concentration of the longer incubation time, the significant increased migration is more effective. Therefore, this study does note C1-inh to promote breast cancer cell proliferation and migration.